Curr Hepatology Rep (2017) 16:184–191 DOI 10.1007/s11901-017-0351-0 HEPATITIS C (J AHN AND A ARONSOHN, SECTION EDITORS) Next-Generation Direct-Acting Antiviral Drug-Based Regimens for Hepatitis C 1,2 1,3,4 1,3,4 Isaac Ruiz & Stéphane Chevaliez & Jean-Michel Pawlotsky Published online: 25 July 2017 Springer Science+Business Media, LLC 2017 Abstract to-use, highly efficient, pangenotypic, once-daily, all-oral, Purpose of Review This article reviews the most recent results interferon- and ribavirin-free. of clinical trials supporting the approval and use of the so-called . . next-generation hepatitis C virus (HCV) direct-acting antiviral Keywords Hepatitis C virus Direct-acting antiviral drugs (DAA) drug regimens, including glecaprevir/pibrentasvir, Next-generation regimens Resistance-associated sofosbuvir/velpatasvir/voxilaprevir, uprifosbuvir/grazoprevir/ substitutions ruzasvir, and AL-335/simeprevir/odalasvir. Recent Findings From 2014 and onwards, HCV DAA drugs belonging to four classes were approved in Europe and the Introduction USA. These combinations are generally safe and well tolerat- ed and yield high rates of sustained virological response Hepatitis C virus (HCV) infection represents a major public (>95%) in most patient populations. However, there is a need health problem, with over 71 million persons chronically infect- for treatment simplification and efficacy in difficult-to-cure ed worldwide [1� ]. The primary goal of HCV therapy is to cure patient populations. Phase II and III clinical
Current Hepatology Reports – Springer Journals
Published: Jul 25, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera